Other Events ·
Valion Bio completes formulation work for novel oral mucosal version of Entolimod using BioViscid platform
VBIOValion Bio, Inc.
Valion Bio, Inc. announced the completion of formulation work for a novel oral mucosal version of its investigational biologic Entolimod, utilizing Shear Kershman Laboratories’ proprietary BioViscid™ drug-delivery platform. This milestone establishes a potential second needle-free development pathway alongside the company's existing injectable program. The next phase will evaluate whether this formulation delivers measurable amounts of Entolimod into the bloodstream to determine systemic exposure and pharmacokinetic profiles. Valion estimates that if approved, the addressable opportunity for this oral formulation could be 10 to 40 times larger than the injectable program, targeting military, firefighter, and law enforcement personnel. Valion Bio, Inc. is a biotechnology company developing biologics for cytoprotection and immune modulation, primarily focused on Acute Radiation Syndrome.